Harm Reduction and Medication Assisted Treatment
Once you register for the course, you will have 30 days from the date of enrollment to complete the course. The date your access expires will be indicated in the Course Summary box on this webpage.
Providers and clinical staff interested in providing treatment and care to individuals diagnosed with Hepatitis C virus (HCV) infection (providers, nurses, behavioral health, linkage navigators, front desk/scheduling, admin, etc.).
- Describe the relationship between Opioid Use Disorder and Harm Reduction with Medicated Assisted Treatment (MAT).
- Address stigma by the public and health providers.
- List the medications used in MAT.
- Recognize the importance of psychosocial support in treating the “whole” person with Substance Use Disorders.
- Review techniques for managing patients who are on MAT in various medical settings (Primary Care, Hospitalized, OTP).
Frank Filippelli, DO, PhD
Dr. Filippelli serves as the medical director at UCS Healthcare. He is a native of Des Moines, Iowa, and attended Lincoln High School and the University of Iowa. Dr. Filippelli received his undergraduate degree in Pharmacy and then completed his Master’s degree and PhD in Medicinal Chemistry at the UI College of Pharmacy. He has worked as a pharmacist in various Des Moines, Iowa City, and Cedar Rapids pharmacies. Dr. Filippelli received post-graduate training at the Dalton Research Center at the University of Missouri, Columbia. After his post-doctoral studies, he pursued an academic career at Drake University College of Pharmacy and Health Sciences from January 1986 through May 1995. He was recognized by Iowa Pharmacy Association and participated in the Young Pharmacist’s Leadership Conference there. After leaving Drake, Dr. Filippelli attended medical school at Des Moines University, graduating in June 1999, and then completed his residency in Family Medicine in 2002 at the Cedar Rapids Medical Education Foundation in Cedar Rapids. Dr. Filippelli began working as a physician in February 2003 with the Iowa Department of Corrections and continues as a primary care provider for the Newton Correctional Facility. He joined UCS Healthcare in November 2010 as medical director, supervising the care of clients undergoing medication-assisted treatment for opioid addiction. In July 2011, he was asked to serve as medical director for the Des Moines facility for Prelude Behavioral Services, which provides short-term inpatient care for treatment of addictions and continues providing medical care to clients with addictions at these facilities.
Recording date: August 12, 2022
Date of original release: August 19, 2022
Most recent review/update: August 19, 2022
Termination date: August 18, 2025
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Primary Care Association. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 1.0 AOA Category 1-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
- Other Healthcare Professionals: This live activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
No ineligible company provided financial support for this continuing education activity.
The planning committee member(s) and speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Julie Baker, MPA, CHCEF - Planning Committee Member and Moderator
- Kristi Barslou - Activity Coordinator
- Mark Hillenbrand, MSW, LISW, RCSW - Planning Committee Member
- Megan Srinivas, MD, MPH - Planning Committee Member
- Megan Westerly, MSN, RN - Activity Coordinator and Moderator
- Frank Filippelli, DO, PhD - Speaker
Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with ineligible companies to disclose. All relevant financial relationships have been mitigated.
- Steven Donnelly, PharmD - Planning Committee Member, Speaker for Gilead
- Douglas LaBrecque, MD - Planning Committee Member, Advisory Board Member for HepQuant
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 1B
- 1.00 CE Contact Hour(s)
- 1.00 IBON